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Health expenditures are growing globally and the causes are somewhat unclear. Baumol’s 
cost disease could potentially act as a viable explanation for rising healthcare costs. The 
formalisation and method constructed by Atanda, Menclova and Reed (2018) allow the 
estimation of two of Baumol’s (1967) original propositions of the cost disease, which are 
seldom tested. The models measure how the healthcare sector’s share of the labour force 
is affected by a) the relative productivity between health and non-health sector, and b) the 
total productivity in the economy. In this thesis, the method is applied to measure if the 
Finnish healthcare sector displays any signs of the cost disease. 
 
The data are gathered from 70 sub-regions in Finland between 2000 and 2016. Sub-
regions are by regional size between municipals and hospital districts. Primary care is 
provided by municipalities and specialised care is provided by hospital regions. The 
Finnish health system is exceptionally decentralised and the cross-regional variation is 
rather large. 
 
The empirical impact of the cost disease is tested with three different fixed effects models, 
similar to the ones used in most of the contributions in the same field of study. The results 
suggest that relative and total productivity are positively related to healthcare share of the 
labour force, which are both anticipated theoretically as well. The effect is statistically 
significant but economically affects only 600-850 employees annually in the health 
sector, which employs around 400 000 people. Therefore, the cost disease is perhaps 
noticeable after a decade-long intersectoral transition in the Finnish labour market.  
 
This thesis strengthens the results of Ministry of Finance (2013) study of the healthcare 
sector which suggests that Finnish healthcare is suffering from Baumol’s cost disease but 
decreases the economical severity of the impact.  
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1. Introduction 
 
Health expenditures have grown rapidly in the last decades in the world and they account 
for a considerable amount of the national income in most developed countries. The 
proportion of health expenditures as a percentage of gross domestic product have 
increased from roughly four percent up to one tenth of the national income in most EU 
and OECD countries in the last 40 years (Medeiros & Schwierz, 2013; OECD, 2019). The 
Finnish healthcare expenditures have doubled in the same period and the costs continues 
to put increasing pressure on the public budget and the fiscal stability. Finland provides 
universal health coverage with 90 percent coverage rate and public health spending is 
expected to grow 2 % annually in the next decade (Dieleman, et.al., 2018). Today, 
managing healthcare expenditures is a challenge of a global scale, which will be even 
more difficult in the future.  
 
The field of health economics has seen many detailed studies about the costs of the health 
sector. One main determinant of rising costs is argued to be the income of the population. 
In fact, no other variables have yielded as clear effects on health expenditure as GDP per 
capita (Gerdtham & Jönsson, 2000; Baltagi & Moscone, 2010; Benavides, 2018). A key 
metric that has naturally derived from the countless estimations is the income elasticity. 
Growth of income increases the seeking of care. However, there is no consensus of 
whether one should consider health services as necessities or luxury goods. Thus, there 
are no clear estimations in this particular field of the future of health expenditures either; 
will their growth continue to increase or eventually slow down. The income elasticity has 
been shown to vary across different levels of income and, somewhat surprisingly, richer 
countries even show a decreasing income elasticity of demand (Di Matteo, 2003). 
 
Given that health expenditures have grown more than income in developed countries, 
implies that there are some omitted factors which have yet to be tested. In recent years, 
many authors have tried to explain this effect with technological differences and Baumol’s 
cost disease (Hartwig, 2008; Colombier, 2012 & 2017; Atanda, Menclova & Reed, 2018). 
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This would explain rising costs if healthcare would be relatively unproductive compared 
to the rest of the economy. Baumol’s cost disease is a theory of the evolution of market 
structures, more specifically how different productivity growth rates can cause higher 
costs in some sectors over time. A non-productive sector would see less cost-decreasing 
innovations and be expected to make less profit and increase selling prices more than a 
productive sector.  
 
Baumol’s (1967) defining characteristics of the cost disease, however, are quite difficult 
to apply in an econometric study. The sufficient data is rarely gathered and, if accessible, 
it might be incomparable with other countries. The idea of using cost disease as an 
explanation for globally rising expenditures might shed light on the ongoing discussion in 
health economics. Even though the theory was born half a century ago, the application in 
empirical research has only begun in the last decade. One difficulty is that there are yet no 
explicit explanatory variables explaining the cost disease. Baumol’s theoretical work 
provided only propositions of suggestible side effects, which are difficult to measure and 
newer studies are constantly trying to construct new models to resolve the problem.  
 
 
1.1. Research objective 
 
The aim of this thesis is to study if the Finnish healthcare market suffers from Baumol’s 
cost disease, by focusing on theory built by Baumol (1967) and following the approach 
that Atanda, Menclova and Reed (2018) have reconstructed. The new approach follows 
Baumol’s (1967) propositions more closely than prior studies of the cost disease in the 
healthcare sector. This thesis will contribute to the discussion by applying the new model 
for smaller regions in one country, instead of using it to measure effects between various 
heterogeneous countries. The data are collected from Finnish sub-regions between 2000 
and 2016. Finland is divided into 70 sub-regions, which each contain 2-7 municipalities, 
and every sub-region belongs to a larger hospital district. Each hospital district has the 
sole responsibility to provide its own specialised care and each municipality is responsible 
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for the provision of primary care, to the extent permitted by the national legal framework. 
The Finnish health system is quite decentralised, which gives the opportunity to study 
varying productivity measures under the same fundamental health structure.  
 
1.2. Disposition 
 
Chapter 2 will introduce the characteristics of the Finnish health system. The chapter 
discusses the organisational structure and the problems with efficiency it faces. Next, in 
chapter 3, the theory behind Baumol’s cost disease is explained and how theory can be 
modified to test empirically. Chapter 3 includes a review of prior studies as from global 
data sets and one study from Finnish healthcare as well. The econometrical method and 
the data of Finland is presented in chapter 4. Chapter 5 presents the results of the main 
estimations in the thesis as well as a discussion of the findings from Finland. Chapter 6 
concludes the thesis. The appendix provides additional definitions, calculations and 
estimation results, which might be beneficial for the reader.   
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2. The Finnish healthcare system 
 
Chapter 2.1 briefly explains the characteristics of the health system in Finland; how it is 
governed and who is responsible for provision of care. Chapter 2.2 is an assessment of the 
health system and discusses the main problems with efficiency today.  
2.1. Overview 
 
Finland spends a relatively small proportion of its income on healthcare. Compared to its 
Nordic neighbours and other similarly governed countries, Finnish healthcare 
expenditures per capita and as a percentage of GDP have generally been less in recent 
years. In 2017, the per capita health expenditures were 4 100 €, which can be translated 
to a total of 9.2 % of the GDP. Health expenditures in Norway, Denmark and Sweden 
have exceeded 10 % of GDP. Approximately 20 % of the total health expenditures in 
Finland are paid with out-of-pocket payments, 70 % is financed with municipal and state 
taxes, and the rest is from other private sources. A third of the health expenditures come 
from private service providers in Finland, and the private sector has grown by 10 
percentage points since 2000. In general, health expenditures have grown drastically in 
the better part of the last sixty years, which much like the rest of the developed countries, 
displays a concerning picture of the future. (Keskimäki et al, 2019; Dieleman, et.al., 2018).  
 
The provision of care in Finland is quite decentralised. There are three levels of 
administration: The Ministry of Social Affairs and Health (MSAH), hospital districts and 
municipalities. MSAH is responsible for the legislation and direction of general health 
policy. MSAH prepares key reforms in healthcare and guides the implementation. The 
municipalities are solely responsible for organising the primary healthcare for their local 
residents. The municipalities may cooperate with public health provision, which is 
common in low-populated neighbouring regions in Finland. In 2020, the number of 
municipalities is 311, of which 70 % have under 10 000 inhabitants. Hospital districts are 
federations of municipalities and they are responsible for specialised medical care 
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provision. Specialised medical care includes examinations and treatments in hospitals, 
which are performed by medical specialists. There are 20 different hospital districts and 
every municipality must be a member of one. Three quarters of the hospital districts are 
inhabited by more than 100 000 people, one of which has 30 % of the Finnish population.  
Furthermore, the care of most demeaning and rare diseases in Finland is centralised into 
five university hospitals, which are located in larger cities around the country. The five 
university hospitals do not have any explicit decision-making powers, but they plan the 
care and treatment of the most severe diseases. The flow of information and finances is 
thus quite complicated. The regional differences between Finnish municipalities are 
substantial as well, since the specialised care expenditures as of total health expenditures 
are almost uniformly distributed between 20 and 50 percent. (Keskimäki et al, 2019; 
Statistics Finland, 2019, Ministry of Social Affairs and Health, 2016a)  
 
Figure 2.1 Finnish municipalities, hospital districts and university hospital 
responsibility regions. Note: Municipalities within thin lines, hospital districts within thick lines. 
OYS: Oulu University Hospital. KYS: Kuopio University Hospital. TAYS: Tampere University Hospital. 
TYKS: Turku University hospital. HYKS: Helsinki University Hospital. 
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Every Finnish resident is covered by national health insurance and one in six of the 
population have an additional voluntary health insurance. Out-of-pocket expenses have 
defined price caps in each individual medical case, but the expenses are higher than in the 
rest of the Nordic regions (Ministry of Social Affairs and Health, 2016b). There are three 
channels for first-contact care: the municipal system, national health insurance system and 
occupationally provided care. The municipal system provides the majority of all care and 
acts as gatekeepers for specialised care in public healthcare. The national health coverage 
system reimburses partially costs of prescribed medicines and health visits to private 
facilities. Additionally, many employees are covered by occupational health coverage, 
which is quite well developed in Finland. The private sector has a substantial stake in the 
occupational healthcare system and private care is often obtained much faster than 
publicly provided care. Occupational care is completely free of charge for the patients as 
well. (Teperi et al, 2009; Keskimäki et al, 2019). 
 
 
2.2. Efficiency and productivity 
 
Healthcare system in Finland performs quite efficiently compared to other countries 
around the world. Health outcomes have improved since 2000 and preventable mortality 
rates are below EU average. According to Keskimäki et al (2019), technical efficiency and 
productivity have grown considerably in specialised care and the pharmaceutical sector. 
Other sectors in healthcare perform relatively well compared to other countries, however, 
the allocation of resources between specialised and primary care in Finland is somewhat 
inefficient and unbalanced. Resources for development are provided more toward 
specialised care, which has been visible in the flow of medical professionals between 
sectors as well. Nationally, between 2000 and 2016 the number of patients per physicians 
decreased in health centres by 30 %, whereas it increased in hospitalised care more than 
50 %. The decentralised nature of the health system makes it difficult to tackle this 
problem, since municipalities and hospital regions are on two different administrative 
levels and no clear cooperating procedure is applied. Any acts of reforms or renewals in 
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healthcare are thus difficult to achieve and the interaction between administrative levels 
is considered complex by the decision makers. Public officials in healthcare and executive 
members of NGOs have different perceptions of the organisational structure of the 
healthcare system. The majority would prefer a more centralised system for healthcare 
provision and financing. (Ministry of Social Affairs and Health, 2016a; Keskimäki et al, 
2019) 
 
The access to care is quite unbalanced in Finland and unmet medical needs are 
considerably higher than EU average and the Nordic neighbours. (European Commission, 
2020; Ministry if Social Affairs and Health, 2016b). Within Finland, access to primary 
and specialised care varies drastically depending on the geographical region. This is 
mostly due to small numbers of health centres in low populated municipalities. Waiting 
times is one factor of unmet medical needs, which also is an indicator of productivity. In 
economics, patients’ waiting time can be seen as a function of number of healthcare 
professionals and number of patients. However, the population density is an insignificant 
factor in waiting times in Finland. On average, the proportion of the patients that waited 
over one week for primary care visits was 45 % in 2015 and it increased to 55 % in 2017. 
In fifteen municipalities, the same statistic was less than 10 %, and in five municipalities, 
every patient waited more than one week in 2017 (Finnish institute of health and welfare, 
2020). There have been attempts to reach patients faster in recent years, which have turned 
out to be mostly unsuccessful. One explanation for this might be that a change in waiting 
times usually affects the behaviour of patients. The demand is expected to increase by 
shortening queues, which, in turn, eventually increases the waiting time. Often, it is rather 
difficult to determine the cause and effect of patients’ waiting times in healthcare. 
However, in Atella et al (2019), the results suggest that lowering waiting times increases 
productivity in healthcare more than cost containment and regulation. (Iversen & Lurås, 
2002; Ministry of Social Affairs and Health, 2016a; Keskimäki et al, 2019) 
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Figure 2.2 Efficiency in university hospital responsibility regions 2016. Note: Values 
indexed to the average values in Finland. OYS: Oulu University Hospital. KYS: Kuopio University 
Hospital. TAYS: Tampere University Hospital. TYKS: Turku University hospital. HYKS: Helsinki 
University Hospital. 
Figure 2.2 displays the variation of different efficiency variables in Finnish university 
hospital regions (Finnish institute of health and welfare, 2020).  A large area in the 
coloured hexagons indicates less efficient or unproductive regions. Generally, the Helsinki 
University hospital region (HYKS) would rank as the most efficient healthcare region in 
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Finland according to Table 2.2, where waiting time in primary care is the only indicator 
above the Finnish average. Expenditures per capita are relatively high in OYS and KYS, 
which could be explained by the regions’ low population density. Waiting time for 
primary care is highest in TYKS and HYKS, whereas the waiting time for specialised care 
is shorter than average in these regions. The indicator for health care employees per capita 
has perhaps the lowest regional variation and the morbidity index has the highest.  
 
 
 After the general election in 2015, the government actively tried to improve the health 
and social care system with an extensive reform. The main objective was to centralise the 
system by integrating the provision of primary, specialised and social care under the same 
administrative organ within larger regions. The reform would have, presumably, 
decreased the disparity in healthcare access and helped to control costs. Alongside the 
structural changes, a crucial aim was to give the patients a greater freedom of choice, with 
the intention of increasing the competition in the health sector. However, the size of the 
reform and the partially conflicting objectives concluded with no actions taken and the 
government’s early resignation. The reform was postponed and the current government 
have written a similar structural reform in their Government programme. (Sinervo, 
Tynkkynen & Vehko, 2016; Keskimäki, et al, 2019, Ministry of Social Affairs and Health, 
2016b). 
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3. Theoretical Background and Empirical Review 
 
This chapter presents thoroughly the theory and empirical research of Baumol’s cost 
disease. The following sub-chapter explains how different elements in the market affect 
each other and how they are expected to change. Chapter 3.2 is a review of the known 
contributions for the application of the cost disease in the health sector. Lastly in chapter 
3.3, the new approach to measure the cost disease is explained in great detail. The new 
model is used in the empirical part of this thesis. 
 
 
3.1. Baumol’s cost disease 
 
The cost disease, commonly known as the Baumol’s cost disease, is a theoretical 
framework to show why some sectors of the economy face expanding costs, even though 
other sectors’ costs would remain stable. The key premise is that the output per man-hour 
grows at different rates in every sector of the economy. Some sectors can apply 
technological changes and innovations more naturally than others, which inevitably will 
enlarge the gap in productivity between various sectors over time. The second assumption 
is that the growth in wages is heavily correlated across all sectors. Wages tend to increase 
at the same rate in the whole economy, regardless of the differences in productivity levels.  
Growth in productivity implies that the same output volume can be produced with less 
labour and, therefore, average costs (per input unit) in slowly growing sectors are expected 
to increase as well.  
 
Baumol (1967) introduced the formalised version of the cost disease and derived four 
propositions for the economy that would be visible.  His analysis uses a simplified version 
of an economy with two sectors: a progressive and a non-progressive sector (henceforth 
PS and NPS), in terms of growth in productivity. Firstly, suppose that the output ( 𝑌), in 
both sectors is given by   
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 𝑌𝑁𝑃𝑆(𝑡) = 𝑎𝐿𝑁𝑃𝑆(𝑡) (3.1) 
  
 𝑌𝑃𝑆(𝑡) = 𝑏𝐿𝑃𝑆(𝑡)𝑒
𝑟𝑡, (3.2) 
 
where 𝐿 is the employment in each sector and 𝑎 and 𝑏 are arbitrary positive constants. The 
productivity in the 𝑁𝑃𝑆 is constant over time, while it continuously grows at the rate of 𝑟 
in the 𝑃𝑆.  
 
Secondly, Baumol (1967) assumed that all wages in the economy grow at the same rate 𝑟 
as the rapidly growing sector and remains equal in both sectors for all 𝑡. The equation is 
shown as 
 𝑊(𝑡) = 𝑊0𝑒
𝑟𝑡  . (3.3) 
 
The constant 𝑊0 is an insignificant start value for the wage equation. Furthermore, given 
equations (3.1), (3.2) and (3.3), we can derive the unit costs in both sectors as 
 
 
𝐶𝑁𝑃𝑆(𝑡) =
𝑊(𝑡)𝐿𝑁𝑃𝑆(𝑡)
𝑌𝑁𝑃𝑆(𝑡)
=
𝑊0𝑒
𝑟𝑡𝐿𝑁𝑃𝑆(𝑡)
𝑎𝐿𝑁𝑃𝑆(𝑡)
=
𝑊0𝑒
𝑟𝑡
𝑎
 
(3.4) 
  and 
 
𝐶𝑃𝑆(𝑡) =
𝑊(𝑡)𝐿𝑃𝑆(𝑡)
𝑌𝑃𝑆(𝑡)
=
𝑊0𝑒
𝑟𝑡𝐿𝑃𝑆(𝑡)
𝑏𝐿𝑃𝑆(𝑡)𝑒𝑟𝑡
=
𝑊0
𝑏
  . 
(3.5) 
 
By using (3.4) and (3.5) to show the relative unit cost of both sectors, we have 
 
𝐶𝑁𝑃𝑆|𝑃𝑆(𝑡) =
𝐶𝑁𝑃𝑆(𝑡)
𝐶𝑃𝑆(𝑡)
=
𝑊0𝑒
𝑟𝑡
𝑎⁄
𝑊0
𝑏⁄
=
𝑏𝑒𝑟𝑡
𝑎
 
 
(3.6) 
 
and a change in 𝑡 can be expressed as 
 
 𝜕 (𝐶𝑁𝑃𝑆|𝑃𝑆(𝑡))
𝜕𝑡
> 0  . 
(3.7) 
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P1. The first proposition: Unit costs in the 𝑁𝑃𝑆 will grow unrestrictedly over time, 
while the costs in the 𝑃𝑆 will remain constant. The demand for jobs and the labour 
market equilibrium will eventually produce a same rate of growth in wages in both 
sectors. Assuming that the wages in both sectors grow at the same rate as the 
productivity in the 𝑃𝑆, the burden of labour wage growth will be increasingly 
difficult for the 𝑁𝑃𝑆. The relative costs between sectors increase, which is the key 
problem with Baumol’s cost disease. Prices in each sector are in proportion to their 
costs, therefore, a positive effect of prices in the 𝑁𝑃𝑆 is expected as well.  
 
Following the issue of increasing relative costs between the 𝑁𝑃𝑆 and 𝑃𝑆, we can continue 
the analysis by examining the expected demand for 𝑁𝑃𝑆 goods. Suppose that prices in the 
𝑁𝑃𝑆 market would be in an equilibrium and the price elasticity of demand for its goods 
would be negative1. The relative output on goods in the economy would thus be shown as 
 
 𝑌𝑁𝑃𝑆(𝑡)
𝑌𝑃𝑆(𝑡)
=
𝑎𝐿𝑁𝑃𝑆(𝑡)
𝑏𝐿𝑃𝑆(𝑡)𝑒𝑟𝑡
  . 
(3.8) 
 
Additionally, we can see that 
 
 
lim
𝑡→∞
(
𝑌𝑁𝑃𝑆(𝑡)
𝑌𝑃𝑆(𝑡)
) =
𝑎
𝑏
lim
𝑡→∞
(
𝐿𝑁𝑃𝑆(𝑡)
𝐿𝑃𝑆(𝑡)
∙
1
𝑒𝑟𝑡
) = 0 
(3.9) 
 
if the growth rate in 𝐿𝑁𝑃𝑆(𝑡) is less than the sum of growth rates in both 𝑃𝑆 labour and in 
𝑃𝑆 productivity, which is certainly a reasonable assumption. In other words, the demand 
for 𝑁𝑃𝑆 goods will approach zero over time. 
 
P2. The second proposition: In an economy suffering from unbalanced growth, the 
𝑁𝑃𝑆 will produce less and less goods and the demand will eventually vanish. Only 
markets with highly inelastic price elasticity of demand will survive increasing 
 
1  Goods that cause a negative change in demanded quantity by a price increase. 
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costs. However, the government can keep the ratio of production between these 
sectors constant with transfers. Sometimes, the desired outcome is to maintain a 
constant level of demand and, thus, subsidise the production. This will, 
consequently, lead to higher transfer costs as well, as the difference in the rate of 
growth between the 𝑃𝑆 and 𝑁𝑃𝑆 increases. 
 
The next effect of Baumol’s (1967) cost disease is derived from the assumption that an 
external part, such as the government, is subsidising the production. Given the total labour 
supply 
 
 𝐿(𝑡) = 𝐿𝑁𝑃𝑆(𝑡) + 𝐿𝑃𝑆(𝑡) (3.10) 
 
and by multiplying equation (3.8) with an arbitrary positive constant  
𝑏
𝑎
 we have 
 
 𝑏
𝑎
𝑌𝑁𝑃𝑆(𝑡)
𝑌𝑃𝑆(𝑡)
=
𝐿𝑁𝑃𝑆(𝑡)
𝐿𝑃𝑆(𝑡)𝑒𝑟𝑡
  . 
(3.11) 
 
By keeping the production ratio between both sectors stable, we can write the right-hand 
side of the equation (3.11) equal to a constant 𝛾. Now if we combine equations (3.10) and 
(3.11) we can express the required labour supply in both sectors with the following steps: 
 
 𝐿𝑁𝑃𝑆(𝑡)
𝐿𝑃𝑆(𝑡)𝑒𝑟𝑡
=  𝛾 ⇔ 𝐿𝑁𝑃𝑆(𝑡) =   𝛾 𝐿𝑃𝑆(𝑡)𝑒
𝑟𝑡 
𝐿𝑃𝑆(𝑡) = 𝐿(𝑡) − 𝐿𝑁𝑃𝑆(𝑡) 
𝐿𝑁𝑃𝑆(𝑡) = 𝛾(𝐿(𝑡) − 𝐿𝑁𝑃𝑆(𝑡))𝑒
𝑟𝑡 
⇔ 𝐿𝑁𝑃𝑆(𝑡) =
𝛾𝐿(𝑡)𝑒𝑟𝑡
1 + 𝛾𝑒𝑟𝑡
  . 
 
 
 
𝑎
𝑠
 
(3.12) 
 
The labour function in the progressive sector can be derived in the same way and is 
expressed as 
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𝐿𝑃𝑆(𝑡) =
𝐿(𝑡)
1 + 𝛾𝑒𝑟𝑡
  . 
𝑎
𝑠
 
(3.13) 
 
Finally, if we let the value 𝑡 approach infinity in equation (3.12), the analysis is quite clear: 
 
 
lim
𝑡→∞
𝐿𝑁𝑃𝑆(𝑡) = lim
𝑡→∞
(
𝛾𝐿(𝑡)𝑒𝑟𝑡
1 + 𝛾𝑒𝑟𝑡
) 
= lim
𝑡→∞
(
𝑒𝑟𝑡
𝑒𝑟𝑡
[
𝛾
1
𝑒𝑟𝑡⁄ + 𝛾
𝐿(𝑡)]) = lim
𝑡→∞
𝐿(𝑡) 
1
2
 
 
(3.14) 
 
The required labour supply in the 𝑁𝑃𝑆 increases by time and approaches the limit of the 
total labour supply. 
 
P3. The third proposition: If we hold the produced amount of goods constant in all 
sectors, the labour force of the 𝑃𝑆 will continue to shift towards the 𝑁𝑃𝑆 until the 
employment in the 𝑃𝑆 is zero. Technological changes allow the 𝑃𝑆 firms to operate 
with fewer employees and they must move elsewhere. There seems to be no clear 
evidence that long-term unemployment has changed over time or has drastically 
been affected by technological growth (Lucas & Rapping, 1969; Feldmann, 2013; 
Khraief et.al., 2018). Thus, the change in the 𝑁𝑃𝑆 employees per total labour force 
ought to be positive. It is highly unlikely that a market could run without human 
interaction, however, it is far more important to realise the shift in the employment 
distribution. Suppose that the rate of production is constant, by nature or by 
transfers: now the economy will face a situation where a growing proportion of the 
labour force is entering into a non-productive field of business, making it 
increasingly difficult to enhance the labour productivity.   
 
Baumol’s (1967) final proposition explores the effects of the whole economy if the ratio 
of production quantities between sectors is kept constant. If the relative costs are always 
rising and the total employment is moving to the 𝑁𝑃𝑆, the growth of the national income 
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is going to slow down. Given the properties of the equations above, the rate of growth in 
total production is approaching zero.2 
 
P4. The fourth Proposition: The resulting effects of the cost disease, if the rate of 
production between the two sectors is kept constant, is that the transfers puts 
pressure on the whole economy. The transfers required to retain the same ratio of 
output increases, which will force the growth of the whole economy to slow down. 
This implies that if the three prior effects of the cost disease hold, the economy 
would grow to a finite limit, after which the rate of change in growth would be 
zero. 
 
 
Even though this formalised theory has been known for more than fifty years, it has proven 
to be problematic to estimate econometrically. One concern is that it is questionable to use 
productivity, or its growth, as an identical measurement between two sectors. Baumol 
(1996; 2012) argues in later discussion pieces that prices are a great indicator when 
analysing different markets, seemingly affected by the cost disease. The most important 
effect, according to Baumol, is increasing costs, which naturally influences the prices of 
the end-users. The first proposition (P1) is therefore an essential determinant of disparity 
in prices in the economy.  
 
 
2 See calculations in Appendix B1 
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Figure 3.1 Price indices in different industries in Finland 2000-2019.  
 
Figure 3.1 shows the evolution of the Finnish consumer price index and four other price 
indices, of which the red line graphs are usually seen as part of the 𝑁𝑃𝑆 and the green 
ones undoubtedly part of the 𝑃𝑆. The real-costs increases in both education and healthcare, 
would thus be the difference to CPI. Additionally, it is clear that the real price changes in 
progressive alternatives, vehicle and clothing industries, have been negative over the time 
period (Statistics Finland, 2019). Figure 3.1 reflects the first proposition well. However, 
the unbalanced price growth in an economy is only partially attributed by differences in 
productivity. Sectors with low degree of competition could as easily show similar patterns, 
so price indicators might be insufficient.  Therefore, it is important to review the other 
propositions of the theory and use logical reasoning to verify if the cost disease would be 
truly a problem.  
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Healthcare should show signs of Baumol’s (1967) propositions for other reasons as well. 
First, healthcare is part service industry, which generally shows less technical 
improvements. Secondly, since many countries promote universal health coverage and 
thus subsidise the sector, the demand is likely to increase rather than vanish. This makes 
healthcare suitable for analysis of the third proposition, which requires third-party 
subsidisation or a heavily inelastic price elasticity of demand. Finally, the distribution in 
the labour force in Finland has changed and the healthcare sector has shown growth in 
recent decades (Statistics Finland, 2019), which could be explained with the third 
proposition.  
 
 
3.2.  Empirical review of the cost disease in healthcare 
 
 
In the last 12 years, there has been an intense discussion about Baumol’s cost disease and 
its genuine effect on the globally growing health expenditures. In empirical studies, the 
dominant method is to create a variable, which will measure one of the properties of the 
cost disease and see how it will affect the total health expenditures in the specified region. 
Baumol (1996; 2012) argues constantly that prices are one of the best indicators to show 
the cost disease. However, many other authors find the medical price indices to be 
upwardly biased, due to improved quality of health production and thus troublesome 
measurements of real-price increases. (Triplett, 1999; Hartwig, 2008; Colombier, 2012 & 
2017).  
 
 
Hartwig’s (2008) study was the first systematic approach of testing Baumol’s cost disease 
in healthcare. In his study, he tests how the unbalanced growth affects healthcare 
expenditures in 19 OECD countries within the time period from 1960 to 2004. His 
approach follows closely Baumol’s (1967) theoretical structure, by constructing a variable 
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called the Baumol variable, which measures the essence of the cost disease discussed in 
chapter 3.1. The Baumol variable is calculated by taking the difference of the growth of 
overall wages and growth of total labour productivity, in each country. A positive value 
of said variable indicates a greater wage growth than productivity growth. The method is 
tested econometrically with numerous regression models, where the measurement of 
health expenditures is the dependent variable and the Baumol variable acting as an 
endogenous independent variable. The models are controlled by several known 
determinants of health expenditures as well, such as growth of national per capita income 
and employment. The results of Hartwig’s (2008) study suggest that Baumol’s cost 
disease is a significant explanatory factor of rising expenditures of healthcare.  
 
The Finnish Ministry of Finance (2013) estimate the Baumol variable’s effect on health 
expenditures from a Finnish time series data sample between 1975 and 2011. The 
econometrical approach is the same as Hartwig (2008), and the results of the estimations 
show similar coefficients. However, the estimations of the Baumol variable are 
problematic according to Ministry of Finance (2013). The multicollinearity in the model 
is severe and the autocorrelations in the variables might distort the effect. The estimation 
results are quite large which gives support to the Baumol’s cost disease hypothesis in the 
health sector, but the magnitude of the variables’ effects are somewhat unreliable. 
 
Colombier (2012) uses a similar model as Hartwig (2008) to test the increasing health 
expenditures in OECD regions between 1965 and 2007, with a small but important 
correction. A closer examination of Hartwig’s (2008) study reveals that it measures an 
assumption where all labour is allocated to the healthcare sector, which represents the 
non-progressive one. Thus, Colombier (2012) estimates econometrically the same model, 
corrected by the healthcare sector’s share of total labour. As expected, the result’s 
estimates show a much lower effect of the Baumol variable than Hartwig (2008), but a 
significant effect nonetheless. Colombier (2012) diminishes the impact of Baumol’s cost 
disease as a severe threat and determinant of the growing costs of health. 
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Bates and Santerre (2013) use the same method as Colombier (2012) to test the effect in 
the United States, by using a state-level panel between 1980 and 2009. The main differing 
factor from the abovementioned studies is that Baumol’s cost disease is tested only in one 
individual country. The results of the estimations are quite similar to Colombier (2012); a 
statistically significant but economically meaningless effect. Additionally, Bates and 
Santerre (2013) extend the method by doing a two-stages least squares (2SLS) estimation 
on how the Baumol variables affect health expenditures, in order to eliminate the possible 
endogeneity bias that may occur in a traditional state-fixed effects method. They use the 
housing-price inflation as an instrument for the Baumol variable. Wage growth is one part 
of the Baumol variable and since wages generally correlate with the prices of housing, it 
should perform as a reasonable instrument in the regression. The results of the 2SLS-
model yield a threefold increase in the effect of the Baumol variable, compared to the first 
estimations of Bates and Santerre (2013). The authors’ study raises the relevance of the 
cost disease in health production. 
 
 
Colombier’s (2017) study is an addition to his earlier paper, where he follows the 2SLS 
method which Bates and Santerre (2013) constructed. Colombier (2017) uses data of 
twenty OECD countries from 1970 to 2010 and uses the growth of the manufacturing 
sector as an instrument for the Baumol variable. The manufacturing industry certainly 
affects the growth of productivity in the entire economy and is exogenous to health 
expenditures. Colombier’s (2017) model produces higher estimations of the Baumol 
variable than his previous study (Colombier, 2012) provided, and the coefficient is similar 
to Bates and Santerre (2013).  
 
Atanda, Menclova and Reed (2018) build a different method to characterize the cost 
disease, by measuring how the healthcare share of the labour force and relative prices of 
health goods react to productivity growth (method discussed more closely in chapter 3.3). 
They studied 28 OECD countries in 1995-2016, and different sectors of the U.S. economy 
between the period of 1947 and 2016. Their findings are neither robust nor significant.  
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In a later paper, Atanda and Reed (2019) even write that their results show “no evidence 
to support the existence of Baumol’s Cost Disease” in healthcare and generally eradicate 
the Baumol variable’s effect on health expenditures. Their conclusions are harshly 
different from others’, which is certainly interesting given that they ultimately study the 
same data as the prior studies in the field (Colombier, 2012 & 2017; Bates & Santerre, 
2013). 
 
 
3.3. The new model 
The propositions in chapter 3.1 are seldom tested in health expenditure studies. The main 
objective tends to be to test the difference in the growth of wages and the growth of total 
productivity. In Atanda, Menclova and Reed (2018), the original theory was rebuilt by 
examining the propositions that Baumol (1967) suggested. The underlying propositions 
are tested by excluding the Baumol variable (see chapter 3.2), since their model is partially 
built by using only the total productivity of the economy. The theory (Atanda, Menclova 
& Reed, 2018) shows mathematically that Baumol’s propositions should be visible only 
with the total productivity variable at time 𝑡, excluding the variable for difference in 
productivity. The authors’ formalization uses the disparity in productivity between NPS 
and PS as well, but they argue that the variable would be incomparable in cross-country 
data collections. Therefore, they show how the disparity variable would change if the total 
economy-wide productivity changes (see chapter 3.3.2). The formalized and testable 
versions of the cost disease propositions are displayed in chapters 3.3.1 and 3.3.2. 
 
 
 The relative productivity method 
 
The first assumption, similar to Baumol (1967), is that the only input factor to the 
production is labour. Let the production of healthcare (𝐻) and the remaining economy 
(𝑁𝐻) be written as 
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 𝑌𝐻 = 𝐿𝐻  (3.15) 
 
 𝑌𝑁𝐻 = 𝜙𝐿𝑁𝐻  , (3.16) 
 
where 𝜙 is defined as the relative productivity between these sectors, measured in terms 
of output per labour as  
 
𝜙 =
𝑌𝑁𝐻
𝐿𝑁𝐻
⁄
𝑌𝐻
𝐿𝐻
⁄
=
𝑌𝑁𝐻𝐿𝐻
𝑌𝐻𝐿𝑁𝐻
  . 
 
(3.17) 
 
The productivity of healthcare is thus generalized to one, and 𝜙 > 1 suggests that the 
productivity in 𝑁𝐻 is higher than in healthcare. The variable 𝜙 measures thus the 
productivity gap and is one of the key elements in this analysis. 
 
Furthermore, by assuming an equilibrium where demand is equal to the supply in the rest 
of the economy, we define the percentage of 𝑁𝐻 demand of the total output as a variable 𝑘, 
so that  
 
 𝑘𝑌 = 𝑌𝑁𝐻 (3.18) 
 
and the equation (3.16) can be substituted to (3.18) as  
 
 𝑘𝑌 =  𝜙𝐿𝑁𝐻  . (3.19) 
 
Naturally, the whole labour supply 𝐿 is the sum of both sectors’ labour and the production 
𝑌 is a function of labour productivity, so that 
 
 𝐿 = 𝐿𝐻 + 𝐿𝑁𝐻 
 
(3.20) 
 𝑌 = 𝐿𝐻 + 𝜙𝐿𝑁𝐻  . (3.21) 
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By writing the whole 𝑁𝐻 labour supply given equation (3.19) as 
 
 
𝐿𝑁𝐻 =
𝑘𝑌
𝜙
  , 
(3.22) 
 
we get 𝐿𝑁𝐻 and 𝐿𝐻 as functions of each other: 
 
𝐿𝑁𝐻 = (
𝑘
𝜙
) (𝐿𝐻 + 𝜙𝐿𝑁𝐻) 
 
 
 
𝐿𝑁𝐻 =
𝑘
𝜙(1 − 𝑘)
𝐿𝐻 
(3.23) 
 
 
𝐿𝐻 =
𝜙(1 − 𝑘)
𝑘
𝐿𝑁𝐻  . 
(3.24) 
 
By substituting equation (3.20) in equations (3.23) and (3.24), and dividing both sides 
with the total labour, we get both sectors’ share of the labour force with 
 
 𝐿𝑁𝐻
𝐿
=
𝑘
𝑘 + 𝜙(1 − 𝑘)
 
(3.25) 
 
 𝐿𝐻
𝐿
=
𝜙(1 − 𝑘)
𝑘 + 𝜙(1 − 𝑘)
  . 
(3.26) 
 
We have now one measurable hypothesis of the cost disease, discussed in chapter 3.1. The 
third proposition in Baumol’s (1967) suggests that if the ratio of production between NPS 
and PS is held constant, the employment in the economy must move towards the NPS. 
The new model (Atanda, Menclova & Reed, 2018) shows this proposition as well. The 
first derivative of equation (3.26) with respect to 𝜙 can be shown as 
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 𝜕 (
𝐿𝐻
𝐿 )
𝜕𝜙
=
𝑘(1 − 𝑘)
(𝑘 + 𝜙(1 − 𝑘))2
 
 
 
and since both 𝑘 and 𝜙 are by definition greater than zero, we get 
 
 𝜕 (
𝐿𝐻
𝐿 )
𝜕𝜙
> 0  . 
 
(3.27) 
 
Therefore, if the supply of health is kept constant, a change in relative productivity would 
result in a growing portion of the population working in healthcare. Additionally, the 
properties of the equation anticipates that a negative change in 
𝐿𝐻
𝐿
 with respect to 𝑘, or 
 
 𝜕 (
𝐿𝐻
𝐿 )
𝜕𝑘
=
−𝜙
(𝑘 + 𝜙(1 − 𝑘))
2 < 0  , 
 
(3.28) 
 
when 𝜙 > 0. Equation (3.28) measures the market effect if the demand for 𝑁𝐻-goods 
grows. The change is quite intuitive; if the production in either sector rises, more labour 
is required in that sector when the production gap is held constant.  
 
In conclusion, we express the 𝐻 proportion of the labour force as an equation of demanded 
ratio of 𝑁𝐻 goods in the economy (𝑘), and a measurement of the disparity in productivity 
(𝜙), with equation (3.26). This measures elements of P2 and P3 as discussed in chapter 
3.1. As a result, the work done by Atanda, Menclova and Reed (2018) gives us equations 
(3.27) and (3.28) as two testable consequences of Baumol’s cost disease.  
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 The total productivity method 
 
Atanda, Menclova and Reed (2018) construct their econometrical methods without the 
disparity variable (𝜙). The argument is that the necessary comparable data to generate the 
variable is unavailable for a cross-country panel and would consequently be pointless. 
Their analysis, however, is generated from all the variables in chapter 3.3 and uses the 
same theoretic assumptions, but the main variable to measure the Baumol’s cost disease 
is the cross-sector productivity in each country. The mathematical proof presented in the 
study is built the following way:  
 
Given the equation (3.21), we can obtain the weighted average productivity in the 
economy with  
 
 
𝑃𝑟𝑜𝑑 =
𝑌
𝐿
=
𝜙𝐿𝑁𝐻 + 𝐿𝐻
𝐿
= 𝜙 (
𝐿𝑁𝐻
𝐿
) +
𝐿𝐻
𝐿
 
(3.29) 
 
and the labour shares in both sectors are in itself functions of 𝜙, which means that 
 
 𝑃𝑟𝑜𝑑 = 𝑓(𝜙). (3.30) 
 
If we only can use the economy-wide productivity (𝑃𝑟𝑜𝑑) to demonstrate the effect in 
equation (3.27), we will need to prove that 
 
 𝜕 (
𝐿𝐻
𝐿 )
𝜕𝑃𝑟𝑜𝑑
=
𝜕 (
𝐿𝐻
𝐿 )
𝜕𝜙
∙
𝜕(𝜙)
𝜕𝑃𝑟𝑜𝑑
> 0   
(3.31) 
 
in order to estimate that there is a positive change in the health share of the labour force if 
the productivity increases. Since  
𝜕(
𝐿𝐻
𝐿
)
𝜕𝜙
 is already shown before, sufficient proof of 
equation (3.31) can by substitution of equations (3.25) and (3.26) be derived the following 
way:  
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𝑃𝑟𝑜𝑑 =
𝑌
𝐿
= 𝜙 (
𝐿𝑁𝐻
𝐿
) +
𝐿𝐻
𝐿
= 𝜙
𝑘
𝑘 + 𝜙(1 − 𝑘)
+
𝜙(1 − 𝑘)
𝑘 + 𝜙(1 − 𝑘)
 
=
𝜙
𝑘 + 𝜙(1 − 𝑘)
 
 
 
(3.32) 
and 
 𝜕𝑃𝑟𝑜𝑑
𝜕𝜙
=
𝑘
(𝑘 + 𝜙(1 − 𝑘))
2  . 
(3.33) 
 
The variable 𝑘 is by definition positive, which means that  
𝜕𝑃𝑟𝑜𝑑
𝜕𝜙
> 0 for every 𝜙 ∈  ℝ+. 
The 𝑃𝑟𝑜𝑑 function is unique and strictly increasing. Therefore, there exists an inverse 
function 𝑓−1(𝜙) and it is derived as 
𝑓−1(𝜙) = 𝜙 =
𝑃𝑟𝑜𝑑 ∙ 𝑘
1 − 𝑃𝑟𝑜𝑑 ∙ (1 − 𝑘)
  . 
(3.34) 
 
The derivate of 𝜙 with respect to 𝑃𝑟𝑜𝑑 is  
𝜕𝜙
𝜕𝑃𝑟𝑜𝑑
=
𝑘
(1 − 𝑃𝑟𝑜𝑑 ∙ (1 − 𝑘))
2 
(3.35) 
 
and given the properties of the used variables,  
𝜕𝜙
𝜕𝑃𝑟𝑜𝑑
 is greater than zero as well. 
Therefore, the inequality in equation (3.31) holds, an increase in the total productivity will 
result in a higher share of labour in healthcare as well, similar to the effect in equation 
(3.27). 
 
With this proof (Atanda, Menclova & Reed, 2018), we can measure the same effect in 
healthcare labour by a change in the total productivity (𝑃𝑟𝑜𝑑), as we would with the 
relative productivity between health and non-health sector. This is extremely useful when 
estimating effects from a cross-country data panel, since the output or labour in the health 
sector is rarely available. Baumol’s third proposition will be tested in this study by 
estimating if both  
𝜕(
𝐿𝐻
𝐿
)
𝜕𝜙
 and 
𝜕(
𝐿𝐻
𝐿
)
𝜕𝑃𝑟𝑜𝑑
 is greater than zero.  
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4. Method 
This chapter presents the methodological approach to evaluate if the Finnish healthcare 
suffers from Baumol’s cost disease. Chapter 4.1 describes and displays the gathered data, 
and the following part shows how it is applied in an econometric analysis.  
4.1. Data 
The data used in this study is a strongly balanced panel of Finnish sub-regions between 
2000 and 2016 (Statistics Finland, 2019; Finnish institute for health and welfare, 2020). 
Finland is divided into 19 regions, which each contains between one to seven sub-regions. 
The total number adds up to 70 sub-regions, 67 of which are on the mainland Finland. 
Figure 4.1 shows the geographical division of Finnish sub-regions. 
 
 
Figure 4.1 Population (A) and health output in EUR (B) in Finnish sub-regions in 2016. 
Note: the colour distribution is divided into the 5th, 25th, 50th, 75th and 95th percentiles. 
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The Finnish sub-regions, shown in Figure 4.1, contain between two to seventeen 
municipalities, depending on population and land area. The dark red-coloured areas in 
4.1A; Helsinki, Tampere and Turku sub-regions, represent 40 % of the nation’s 
population. Finnish inhabitants are somewhat clustered around the most populated 
municipalities and centred more towards the southern part of the country. 
 
Regarding healthcare, the Finnish municipalities are responsible for primary care in their 
own regions and the provision and responsibility of specialised care services are divided 
into 20 Hospital districts nationally (Local and Regional Government Finland, 2020; 
Keskimäki et al, 2019). Considering the regional size, sub-regions are conveniently 
located between municipalities and hospital regions. This will hopefully capture elements 
of both primary care and specialised care in the regressions in this thesis. In Finland, 
sufficient data at the municipal level is unavailable and gathering data at the hospital level 
would drastically decrease the number of observations and potentially place too much 
emphasis on specialised care provision. Either way, the Finnish health-system is highly 
decentralised, which allows sizeable variations in interregional health statistics.  
 
The main variables in this study, which are used in the models in chapter 3.3, are the ratio 
of labour working in healthcare, the total production of non-healthcare goods and the 
relative labour productivity between non-healthcare and healthcare production. One 
strength in this study is that it uses data provided by Statistics Finland’s (2019) of total 
production, divided separately by industry sector in the Finnish economy. In this study, 
the healthcare sector is represented by the sum of total production in human health and 
social work activities (Statistics Finland, 2019). Figure 4.1 B illustrates the variation of 
healthcare output per population.  
 
As shown and discussed above, there are clear differences in health related variables 
between Finnish sub-regions. Interestingly, the variation is geographically disseminated 
and there are no clear differences between hospital districts. Therefore, it is useful to 
measure the effects of the cost disease with a cross-region fixed effects model. Fixed 
effects models are often used in health economics studies because they can measure more 
Kristian Gästgifvars 
28 
 
causal effects for variable coefficients by excluding the time and cross-regional effects. In 
cross-country panels, the relative productivity variable is yet to be observable, since the 
data of production in each sector is unavailable and often non-comparable between 
countries (Atanda, Menclova & Reed, 2018). The cross-regional Finnish data, however, 
is gathered and measured by the same statistics institution.  
 
 
Table 4.1 Descriptive statistics of Finnish sub-regions 2016. 
 
Variable 
All economic regions Regions divided by income¹ 
   High Low 
Mean min / max Std.dev Mean Std.dev Mean Std.dev 
𝐿𝐻𝐿 , % 15.9 10.4 / 23.0 2.7 15.9 2.7 16.1 2.6 
𝜙 ³ 2.44 1.41 / 8.34 0.85 2.47 0.88 2.28 0.55 
𝑘 , % ³ 92.3 86.7 / 98.2 2.3 92.4 2.4 91.9 2.0 
% of private health 
production³ 
31.9 3.4 / 77.1 7.3 32.3 6.3 29.7 1.1 
Costs of specialised³ 
healthcare per capita 
1198 1006 / 1744 182 1174 162 1325 225 
Cancer index ² 100 64 / 112  9.0 101 7.5 92 12.2 
Circulatory disease 
index ² 
100 45 / 150 12.5 94 15.7 108 21.5 
Population ³, x 1000 78.6 2.12 / 1519  22.5 132 256.9 25.1 14.3 
GDP per capita ³ 39 350 18 998 / 74 160/ 9517 41 705 8498 26 950 2063 
Age > 64 , % ³ 20.9 14.7 / 35.7 4.5 19.8 3.8 26.8 3.8 
Unemployment, % ³ 13.3 2.7 / 19.3  2.5 13.3 2.3 13.3 3.2 
Observations ³ 70 - - 35 - 35 - 
Note: Values are weighted by population in each region. Monetary values measured in EUR. ¹ The division 
is calculated from median values GDP per capita. ² Higher values indicate higher level of morbidity, index 
100 = total population in Finland, 2016. ³ Average values unweighted by population.  
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Table 4.1 presents data on variables likely to affect the Finnish healthcare sector, for the 
whole population and separately for high- and low-income regions. Most variables are 
weighted by population, since the variation is larger in small sample groups, and the 
regions with low population will unlikely represent the average population in Finland. The 
first three variables are applied in the theoretical method of measuring Baumol’s cost 
disease (see chapter 3.3). The variable 𝐿𝐻𝐿 is calculated by dividing the number of 
employed individuals in the healthcare sector by the total labour force in each region. In 
absolute terms, approximately 400 000 people are working in the health sector in Finland 
and the variation between regions is actually quite small. The variable 𝜙 measures the 
disparity in productivity between non-health and health sectors. As we can see in Table 
4.1, the labour productivity in the non-health sector is considerably higher. The average 
productivity in the rest of the economy is more than two times higher than in healthcare, 
which gives support to the main hypothesis in this study. The variable 𝑘 represents the 
demand for non-health goods. 𝑘 is calculated by subtracting the healthcare output from 
total output and dividing the difference by the total output in the economy. Thus, the share 
of demand for health goods is represented by (1 − 𝑘). The demand for healthcare goods 
adds up to nearly 10 % of the total demand and the regional variation is rather large.  
 
The next four variables in Table 4.1 represent the institutional variables in healthcare. 
Private health production counts for almost a third of the total health production in 
Finland, thereby making it a crucial factor in the analysis. In the last twenty years, the 
private health sector has grown by ten percentage points. The costs of specialised care 
varies substantially in different regions and the mean value is quite high, compared to the 
total health outputs per capita in Figure 4.1 B. Variables Circulatory disease index and 
Cancer index measure the morbidity level in sub-regions of the most common causes of 
death in Finland (Keskimäki et al, 2019). Both indices differ considerably between high- 
and low-income regions, cancer being more common in wealthier regions and circulatory 
diseases affecting more low-income regions.  
 
The rest of the rows in Table 4.1 show the demographic and economic variables. The 
demographic variables are often regarded essential influencing factors in healthcare 
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system analyses (Hitiris, 1997) and especially income considered as the most important 
determinant of health expenditures (Gerdtham & Jönsson, 2000; Baltagi & Moscone, 
2010; Benavides, 2018). The age structure, population and income are therefore controlled 
for in this study, as well. The population in Finland has grown only slightly in the last two 
decades, at a yearly growth rate of 0.4 percent. Concurrently, the age structure has changed 
drastically. The proportion of elderly population has grown with five percentage points 
between 2000 and 2016, and accounts now for approximately one fifth of the Finnish 
population. In low-income regions, the same statistic is more than a 25 %. In some regions 
the ratio of over 64-year-old inhabitants is nearly 40 %. The variation in demographic 
variables between sub-regions is thus quite large.  
 
 
4.2. Primary empirical model 
 
This study will use a two-way fixed effects regression model, to test Baumol’s (1967) cost 
disease hypothesis, i.e. the equations (3.27) and (3.28) discussed in chapter 3.3. According 
to the theoretical framework (Atanda, Menclova & Reed, 2018), there are two affecting 
variables in the healthcare share of the labour force equation (see eq. (3.26)), thus giving 
two endogenous variables in the regression. For the Finnish healthcare system, the 
measured model is specified the following way: 
 
 𝐿𝐻𝐿𝑖𝑡 = 𝛽1𝜙𝑖𝑡 + 𝛽2𝑘𝑖𝑡 + 𝜐 ∙ 𝑍𝑖𝑡 + 𝑢𝑖𝑡   , (4.1) 
 
where the error term is sum of non-observable region-specific effects and secular year-
specific effects and individual time trends, defined as 
 
 𝑢𝑖𝑡 = 𝛼𝑖 + 𝜂𝑡 + 𝜇𝑖 ∙ 𝑡 + 𝜀𝑖𝑡   .  
 
𝐿𝐻𝐿 is the proportion of the labour force working in the healthcare sector, 𝜙 is the relative 
productivity between sectors and 𝑘 the ratio of production in the non-healthcare sector. 
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All endogenous variables are explained in greater detail in chapter 3.3 and Table A1. 
Equation (4.1) includes also a dot product of a vector of exogenous explanatory 
variables, 𝑍, and a vector of coefficients, 𝜐. The vector 𝑍 contains several variables (see 
Table 4.1 & Table A1), which are used in numerous prior health economics studies, that 
reviews the determinants of healthcare expenditures (Gerdtham & Jönsson, 2000; 
Hartwig, 2008; Colombier, 2012; Bates & Santerre, 2013). The econometric model uses 
only unique observations in region 𝑖 at time 𝑡 ( 𝑖 = 1, … , 67; 𝑡 = 1, … , 17) and excludes 
the time and regional invariant effects of healthcare. Thus, any economic trends affecting 
the whole country, such as inflation and price indices, cannot be controlled for and will 
not be included in the model. Additionally, by allowing the model to be controlled for 
individual time trends will absorb the heterogeneity that might arise with time between 
regions. (Allison, 2009; Wooldridge, 2007 & 2012; Dynarski, Jacob & Kreisman, 2018). 
 
 
4.3. Other variable measurements 
 
Due to insufficient data, Atanda, Menclova and Reed (2018) measures Baumol’s cost 
disease with the same model as in equation (4.1), but with different endogenous variables. 
As we saw in chapter 3.3.2, proposition 3 in Baumol’s (1967) theory can be measured 
with the economy-wide productivity. Atanda, Menclova and Reed (2018) utilize this 
property and substitute the relative productivity variable (equation (3.17)) with the total 
productivity in different countries, measured as the ratio of GDP to the number of hours 
worked. In this study, the same detail will be applied i.e. substituting 𝜙𝑖𝑡 in equation (4.1) 
with the variable 𝑃𝑟𝑜𝑑𝑖𝑡, which is measured as 
 
 
𝑃𝑟𝑜𝑑 =
𝐺𝐷𝑃
𝑡𝑜𝑡𝑎𝑙 ℎ𝑜𝑢𝑟𝑠 𝑤𝑜𝑟𝑘𝑒𝑑
  . 
(4.2) 
 
Additionally, dividing the production by the total number of working hours might raise 
the accuracy of calculating the productivity. By measuring the required time of producing 
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one unit of goods instead of number of employees in the sector, eliminates the possible 
omitted effect that could emerge from differences in length of standard working days 
between sectors. The standard equilibrium for working hours might even be different in 
each sub-region depending on the economic incentives and demographics (Alesina, 
Glaeser & Sacerdote, 2005). 
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5. Results 
 
This chapter presents the results of the econometric models presented in chapter 4.2. The 
results in this chapter follow closely the rebuilt theory by Atanda, Menclova and Reed 
(2018), which is presented in chapter 3.3.  
5.1. The relative productivity method 
 
Table 5.1 summarises the determinants of health sector labour share with three different 
OLS estimation methods: a region-fixed effect estimation (FE), a two-way fixed effect 
(2WFE) estimation, which includes year dummy variables, and finally a fixed effect 
estimation with region-specific time trends (FErTT). All three models show the raw effect 
of the variables, which theoretically should affect the dependant variable (Atanda, 
Menclova and Reed, 2018), followed by a set of control variables affecting both the 
demand and supply of health production. All estimations are controlled for demographic 
and economic variables as well. The logarithmic dependent variables are chosen in non-
percentage variables by tentatively maximising the coefficient of determination (𝑅2) in 
the model and applying it in numerically large observation values. GDP/cap growth rate 
is measured with the first difference of the natural logarithm of per capita income 
(𝑑. ln (𝐺𝐷𝑃 𝑝𝑒𝑟 𝑐𝑎𝑝𝑖𝑡𝑎)), which is a standard way of controlling the effect of income 
elasticity in recent health economics studies. It mitigates the problem of non-stationary 
time series and spurious effects. The coefficients show the significance level with cluster-
robust standard errors, which are found to be more reliable when the regression sample is 
clustered by regions, much like the Finnish data set does. (Barros, 1998; Bowerman, 
OConnell & Koehler, 2005; Abadie, Athey, Imbens, & Wooldridge, 2017) 
 
In the first column in Table 5.1, both main variables are significantly different from zero. 
The effect of the relative productivity (𝜙) is positive and share of demand for non-health 
goods (𝑘) is negative, which is in line with the predictions in equations (3.27) and (3.28). 
By adding the control variables in column 2, the coefficient of the main variables remains 
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virtually identical to the first model. All institutional variables have a small insignificant 
effect. Growth of GDP per capita is negative but insignificant, which is unusual given the 
strong relationship between health expenditure and income, but the effect is similar to 
what Atanda, Menclova and Reed (2018) estimated. The age structure seems to have a   
quite large and significant effect on the labour in healthcare. The higher the proportion of 
young and elder population, the larger share of health personnel is required in the region. 
The positive effect is intuitive, since high birth rate regions employ more gynaecologists 
and paediatricians in maternity and child health clinics and the older population generally 
require care more frequently. The estimated effect of unemployment in the second column 
in Table 5.1 is statistically no different from zero. In other words, the results suggest that 
the health sector is unaffected by the changes in the total labour force. High public 
indebtedness should intuitively affect the spending and saving in each municipality and 
thus the planning of primary care provision. However, there is no evidence that 
indebtedness would affect health production in column 2 either.  
 
The models in the third and fourth column in Table 5.1 include a set of year dummies to 
exclude the time-specific effects in Finnish healthcare. The effects of the first two 
variables are both in line with the tested theory and roughly the same as in the regular 
fixed effect model. The effect of the share of under 15-year-old and over 64-year-old 
population is slightly larger and remains significant. Otherwise, the control variables show 
similar results as the first two columns. The F-test of the time dummies are jointly 
significantly equal to zero, indicating that the 2WFE is more appropriate than the FE 
model (Baum, 2006). However, 𝑅2 is only slightly greater in the 2WFE alternative, which 
means that time-specific changes offer only little explanation of the variation in LHL.  
 
The third model combines the fixed effects with individual time trend effects. Therefore, 
the model allows variables to grow at different rates in each region and control for 
unobserved time trends that might affect health sector share of the labour force within 
every region (Bates & Santerre, 2015). The FErTT models in Table 5.1 show a slightly 
larger positive effect for the relative productivity variable, but ultimately the significant 
coefficient remains close to the estimations in columns 1–4.   
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Table 5.1 Fixed effects estimations with relative productivity. Dependant variable: 
Healthcare sector share of the labour force (LHL). 
 Fixed effects 
 
Two-way fixed 
effects 
 
Fixed effects with 
region specific time 
trends 
VARIABLES  (FE)  (2WFE)  (FErTT) 
 (1) (2) (3) (4) (5) (6) 
ln (𝜙)  0.0760** 0.0708** 0.0690** 0.0720** 0.0810** 0.0793** 
 (0.0051) (0.0059) (0.0057) (0.0054) (0.0048) (0.0049) 
𝑘  – 1.386** – 1.332** – 1.167** – 1.340** – 1.254** – 1.429** 
 (0.0877) 
 
(0.0872) (0.1190) (0.0873) (0.1380) (0.0845) 
Private health production  – 0.008 
(0.008) 
 – 0.012 
(0.008) 
 – 0.018** 
(0.004) 
       
ln (costs of specialised 
care/capita) 
 – 0.002 
(0.004) 
 – 0.005 
(0.005) 
 0.002 
(0.002) 
       
ln (sickness allowances)  – 0.006  – 0.003  0.004 
  (0.006)  (0.007)  (0.005) 
ln (cancer index)  – 0.001  – 0.001  – 0.002 
  (0.004)  (0.004)  (0.004) 
ln (circulatory disease 
index) 
 0.001 
(0.003) 
 0.004 
(0.003) 
 0.001 
(0.002) 
       
GDP/cap growth rate  – 0.002  – 0.001  – 0.001 
  (0.002)  (0.002)  (0.001) 
Age > 64  0.141**  0.242**  0.101 
  (0.035)  (0.058)  (0.062) 
Age < 15  0.218*  0.366**  0.015 
  (0.106)  (0.113)  (0.093) 
Unemployment   0.009  0.010  0.024 
  (0.033)  (0.058)  (0.017) 
Relative public 
indebtedness 
 0.002 
(0.005) 
 – 0.001 
(0.006) 
 – 0.003 
(0.005) 
       
Constant 1.368** 1.300** 1.165** 1.241** 1.241** 1.353** 
 (0.080) (0.099) (0.109) (0.108) (0.126) (0.081) 
       
Observations 1 190 1 005 1 190 1 005 1 190 1 005 
Adj. 𝑅2 0.698 0.790 0.740 0.798 0.966 0.978 
Number of regions 70 67 70 67 70 67 
Time fixed effects No No Yes Yes Yes Yes 
Indiv. region time trends No No No No Yes Yes 
F-test (time effects) - - 𝑝 =.000 𝑝 =.001 𝑝 =.000 𝑝 =.000 
F-test (linear time trends) - - - - 𝑝 =.000 𝑝 =.000 
Note: Cluster-robust standard errors in parentheses. F-test: tests if the specified variables are jointly 
significant in the model, H0: no significant effects. ** 𝑝 <0.01, * 𝑝 <0.05. 
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The non-health sector demand is negative and significant. Given the earlier models, the 
private health production show interestingly a significant negative effect on health sector 
labour force. The effect is close to those in column 2 and 4, but the standard error in the 
estimation is smaller. This would indicate that the stronger private health sector would 
reduce the effect of Baumol’s cost disease. The additional health variables continue to be 
insignificant, which means that the population’s health status might have no effect on the 
number of health care personnel. The age structure has a smaller impact on 𝐿𝐻𝐿 in the 
FErTT models and the rest of the economic variables remain the same. Models in column 
5 and 6 are tested for an F-test for linear time trend effects as well and the trends are jointly 
significant.  
 
The results show quite robust estimations in all columns (Table 5.1, see Appendix C). The 
effects of the control variables are mostly similar to findings in other health economics 
studies. The Finnish Ministry of Finance (2013) found a significantly positive relationship 
with health expenditure and private production, which would indicate that private 
production has an effect on contributing factor of health production. Private health 
production has negative effects in estimations in Table 5.1, of which one was clearly 
significant. Growth of GDP has no effect on proportion of healthcare labour in Table 5.1, 
which is the case in Atanda, Menclova and Reed (2018) as well. Generally, growth of 
income tends to affect health production positively (Barros, 1998; Gerdtham & Jönsson, 
2000; Bates & Santerre, 2013), but the dependent variable is usually different. The age 
structure seems to have only a slight effect on health production in several studies 
(Ministery of Finance, 2013; Atanda, Menclova and Reed, 2018; Colombier (2017). 
However, the estimations in Table 5.1 show a strong positive effect on the labour in 
healthcare as a control. The age variables have obviously a high correlation with each 
other which might affect the actual coefficient in Finland (see Table A3). The regional 
unemployment seems to be an unimportant factor for the labour force in the health sector, 
which is in line with the estimates of Bates and Santerre (2013; 2015). 
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5.2. The total productivity method 
 
The model, which Atanda, Menclova and Reed (2018) use to estimate the cost disease in 
their paper is applied in this paper as well. As discussed in chapter 4.3, the model in 
equation (4.1) can be tested, and the expected values of the coefficients are the same. The 
estimations and each variable’s effects are presented in Table 5.2, exactly in the same way 
as in table 5.1 except for the first variable.  
 
In Table 5.2, the two first columns present the fixed effect model without controlling for 
year dummies. The effect of the total productivity is significantly positive and the demand 
for non-health goods (𝑘) is negative. The positive effect of ln (𝑃𝑟𝑜𝑑) is less than the effect 
of ln (𝜙) in Table 5.1, which is actually expected in the theory (see calculations in 
Appendix B2). The control variables are widely the same. More private health production 
decreases the number of health care personnel in the area and the effect is significant, 
unlike the corresponding coefficient in Table 5.1 which is much smaller. Otherwise, all 
the institutional variables are insignificant and similar to the first estimations. The growth 
of GDP per capita is negative and the age structure variables are significantly positive. 
Both unemployment and region’s public indebtedness is statistically no different from 
zero. The 𝑅2 value in columns (1) and (2) are approximately half of which they are in 
Table 5.1, which could be anticipated with a more generalised version of the productivity 
measurement of healthcare production.  
 
Columns (3) and (4) show the estimations with time fixed effects (2WFE). The raw model 
with the two endogenous variables fades the effect of total productivity. The effect is close 
to zero and insignificant. However, by adding the group of control variables, the effect of 
the total productivity increases to a similar level as in column (2). The variable 𝑘 has a 
negative significant effect and show more robust effects than 𝑃𝑟𝑜𝑑. Private health 
production is close to its estimations in columns (1) and (2) and significant. Specialised 
healthcare costs, sickness allowances on the morbidity indexes are insignificant in column 
(3) and (4). Economic and demographic variables are roughly the same as in the first two 
columns.  
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Table 5.2 Fixed effects estimations with total productivity. Dependant variable: 
Healthcare sector share of the labour force (LHL). 
 Fixed effects 
 
Two-way fixed 
effects 
 
(2WFE) 
Fixed effect with region 
specific time trends 
 
VARIABLES (FE) (FErTT) 
 (1) (2) (3) (4) (5) (6) 
ln (𝑃𝑟𝑜𝑑)  0.0227** 0.0106** – 0.0001 0.0114** 0.0004 0.0124** 
 (0.0020) (0.0036) (0.0035) (0.0038) (0.0039) (0.0044) 
𝑘  – 0.339** – 0.414** – 0.206** – 0.405** – 0.200** – 0.430** 
 (0.0239) 
 
(0.0322) (0.0265) (0.0332) (0.0276) (0.0347) 
Private health production  – 0.043** 
(0.006) 
 – 0.046** 
(0.007) 
 – 0.057** 
(0.007) 
       
ln (costs of specialised 
care/capita) 
 – 0.004 
(0.003) 
 – 0.007 
(0.005) 
 – 0.000 
(0.004) 
       
ln (sickness allowances)  – 0.010  – 0.002  0.002 
  (0.006)  (0.007)  (0.006) 
ln (cancer index)  – 0.001  0.000  – 0.006 
  (0.004)  (0.004)  (0.004) 
ln (circulatory disease 
index) 
 0.004 
(0.003) 
 0.006 
(0.003) 
 0.009** 
(0.003) 
       
GDP/cap growth rate  – 0.007  – 0.004  – 0.006 
  (0.004)  (0.004)  (0.003) 
Age > 64  0.282**  0.336**  0.207** 
  (0.033)  (0.053)  (0.069) 
Age < 15  0.347**  0.432**  0.379** 
  (0.073)  (0.087)  (0.126) 
Unemployment   – 0.008  0.053  0.004 
  (0.023)  (0.035)  (0.025) 
Relative public 
indebtedness 
 0.007 
(0.004) 
 0.007 
(0.005) 
 – 0.006 
(0.005) 
       
Constant 0.380** 0.444** 0.329** 0.369** 0.331** 0.385** 
 (0.026) (0.051) (0.025) (0.059) (0.028) (0.055) 
       
Observations 1 190 1 005 1 190 1 005 1 190 1 005 
Adj. 𝑅2 0.259 0.444 0.362 0.445 0.897 0.926 
Number Regions 70 67 70 67 70 67 
Time fixed effects No No Yes Yes Yes Yes 
Indiv. region time trends No No No No Yes Yes 
F-test (time effects) - - 𝑝 =.000 𝑝 =.003 𝑝 =.007 𝑝 =.000 
F-test (time trends) - - - - 𝑝 =.006 𝑝 =.000 
Note: Cluster-robust standard errors in parentheses. F-test: tests if the specified variables are jointly 
significant in the model, H0: no significant effects. ** 𝑝 <0.01, * 𝑝 <0.05. 
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The third pair of estimations in Table 5.2 show the variables’ effect on healthcare share 
of the labour force with the FErTT model. Compared to the 2WFE models, the total 
productivity variable behaves in a similar way by having no impact to 𝐿𝐻𝐿 in the raw 
estimation and a significant coefficient with the control variables. The demand for non-
health goods has a quite strong negative effect, which is expected since the level of 
demand should affect the produced quantity of health, thus, affect the labour within the 
sector as well. The percent of private health output has a significant negative impact on 
the health labour force in the sixth column and the age structure remain an essential part 
in the estimations. Given the results in Table 5.2, a younger population requires more 
health care personnel than an older population on average. The rest of the controls are 
similar in columns (4) and (6), except for the level of circulatory disease morbidity rate 
which appears to have a small significant impact.   
 
The total productivity model in Table 5.2 does not show as robust effects as the relative 
productivity alternative in Table 5.1. The effect of the most important variable, 𝑃𝑟𝑜𝑑, 
varies highly in each estimation and has both theoretically (appendix B2) and empirically 
a smaller effect than 𝜙 on 𝐿𝐻𝐿. The phenomenon where the estimated effect changes to 
significant by adding control variables is also evidence of multicollinearity. A change in 
most other variables are thus affecting the change in 𝑃𝑟𝑜𝑑, which in itself has a weak 
explanatory power. However, the results in Table 5.2 show slightly more favourable 
estimations of supporting the existence of Baumol’s cost disease than Atanda, Menclova 
and Reed (2018), but the results are less convincing than the model used in Table 5.1.  
 
 
5.3. Discussion 
 
Table 5.1 seems to capture the effect of Baumol’s cost disease. Both of the expected 
effects in equation (3.27) and (3.28) are visible regardless of the model. An average 
change in 𝜙 would thus result in an estimated 600 – 850 jobs moving either into or from 
the health sector in Finland, ceteris paribus. The yearly change in relative productivity has 
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varied each year between 2000 and 2016. Figure 5.1 illustrates the yearly change in 𝜙 and 
the variation between regions.  
 
 
Figure 5.1 Box graph of the yearly change in relative productivity in Finland. Note: the 
boxes show variability in Finnish sub-regions. 
 
The total number of professionals employed by the health sector is nearly 400 000, thus, 
the yearly impact of the relative productivity on the labour market is modest at best. Given 
the data sample used in this study, there is no clear direction in relative productivity 
variable in the future. The main factor of 𝜙 is the denominator (see eq. 3.17) since the 
economic downturns tend to affect more the production of the non-health sector. In the 
last two decades, the Finnish GDP growth has been mostly negative at two time intervals; 
2008-2010 and 2012-2016. The medium-term growth rate in Finland is 1.5 % (Economic 
Policy Council, 2018).  Due to the world-wide financial crisis in 2008 and the European 
debt crisis which followed soon after, the data sample of the Finnish economy (Statistics 
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Finland, 2019) might fail to capture the real level or actual direction of the productivity 
growth between sectors in the future. Nevertheless, if labour productivity grows with a 
different rate in non-health sectors than in healthcare in Finland a change in the labour 
structure is expected, which is the general idea of Baumol’s third proposition (Baumol, 
1967) of the cost disease. Additionally, assuming the total production will grow with its 
medium-term rate, the impact of the disparity in productivity would be economically 
noticeable in a decade. 
 
Productivity indicators are often criticised for their inaccuracy. The relative productivity 
variable is an imprecise solution for measuring the real impact of the productivity gap. 
Using the same indicator of productivity in different sectors tends to misrepresent the 
actual effectiveness in each sector of the economy (Bernard & Jones, 1996; Van de Walle, 
2008). Cowen (1996) argues in his paper that the main problem with studies of Baumol’s 
cost disease is that growth in quality is often overlooked in the non-progressively growing 
sector. Quality improvements certainly increase the value of the produced goods, and 
sometimes the changes over time occur in an unmeasurable way. In healthcare, the 
measurement of productivity is often corrected for infant-mortality and life-expectancy 
(Afonso, Schuknecht & Tanzi, 2005) and there are many potential ways to improve the 
indicator of the actual level of performance. However, correcting the health sector 
productivity would further misrepresent the relative productivity variable, especially if the 
labour productivity in the rest of the economy would be left uncorrected. Even though the 
productivity values in equations (4.1) and (4.2) are somewhat flawed, the change in the 
labour market is identified by a change in the relative labour productivity between the 
studied sectors. Therefore, the method in this thesis measures the actual problem which 
arises with disparity in labour productivity (Baumol 1967), whether the productivity 
variable measures actual performance within sectors or not.  
 
The results in Table 5.2 are derived from a more generalized model and the coefficients 
between the models show greater variations. A noteworthy difference between the theories 
used in the estimations in Table 5.1 and 5.2 is that the disparity in health sector 
productivity and rest of the economy is merely an assumption in the total productivity 
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model. In an intuitive sense, productivity in the whole economy should not affect the 
health sector labour any more than other sectors if the productivity cannot be observed 
separately, even though it theoretically will (chapter 3.3.2). The difference in productivity 
is excluded from the measurements, which threatens the validity of the model. However, 
there seems to be some evidence to the cost disease argument with the total productivity 
nonetheless, even though the effect is smaller in magnitude than the relative productivity 
variable.  
 
In Finland, health expenditures per capita have grown by 40 % between 2000 and 2016 
and the real prices have grown by almost 20 % (OECD 2019; Statistics Finland, 2019). 
The study by Ministry of Finance (2013) suggests that health expenditures in Finland are 
affected by the difference in productivity, which is in line with the first proposition (P1) 
of Baumol’s cost disease. The demand for health is kept constant with the national health 
insurance and regulated out-of-pocket payments (Keskimäki et al, 2019). The 
subsidisation restricts the demand for health to decline, which would be predicted by the 
second proposition (P2). Given the results in this chapter, the third proposition (P3) is 
visible as well. Thus, the empirical evidence in this study suggests that the healthcare 
sector in Finland would suffer Baumol’s cost disease. In other words, the productivity in 
health sector affects healthcare costs, prices and labour, controlled for the average 
productivity in all other sectors of the economy. Despite the clear signs of the cost disease, 
the effect in the whole economy is quite small. The disparity in productivity explains a 
marginal part of the change in the labour market in Finland, whereas the demand for health 
has a sizeable explanatory power, much like the mainstream conclusions in the field of 
study. Nevertheless, the results suggest that Baumol’s cost disease cannot be excluded as 
an explanation of how health sector has evolved in the past and is going to evolve in the 
future. The overall results are in line with Colombier (2012, 2017) and Bates and Santerre 
(2013, 2015). The effect of Baumol’s cost disease is not quite as high as in Hartwig (2008) 
and Ministry of Finance (2013), and somewhat greater than in Atanda, Menclova and 
Reed (2018).  
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6. Conclusions 
 
The aim of this thesis is to evaluate if the Finnish healthcare sector is affected by Baumol’s 
cost disease. Baumol’s cost disease proposes that a relatively non-productive sector will 
exhibit four consecutive market phenomena over time: 1) the cost per input unit will 
increase. 2) The demand will decline without third-party intervention. 3) The labour force 
will move from the productive sector toward the non-productive sector. 4) The costs of 
third-party intervention will increase and affect the overall economic growth. In countries 
with universal health coverage the third party is naturally the government. The repeatedly 
discussed problem, however, is to use reliable models and measurements to study the 
changes in market structures. This thesis uses a model from a recent study by Atanda, 
Menclova and Reed (2018), which measures the third proposition of the cost disease, 
controlled by the second proposition. The most important factor is the effects of the 
relative productivity variable, which is measured by dividing the labour productivity of 
the health sector by the productivity of the rest of the economy.  
 
The results of the sub-regional-level fixed effect estimations suggest that a positive change 
in the relative productivity will increase the health sector share of the labour force in 
Finland. Additionally, a similar estimation derived from the relative productivity model 
suggest the economy-wide productivity will affect health production positively as well. 
The estimates are mostly statistically significant but trivial from the perspective of the 
entire labour market. Within Finland, an average change of the disparity in productivity 
variable affects under a thousand employees yearly. 
 
This study contributes in two ways to the economic field of research: Firstly, Baumol’s 
cost disease can be used as an explanation for growing health expenditures. The impact is 
small but visible. Secondly, despite the dispute of the theory, Baumol’s (1967) framework 
seems to explain the evolution of different sectors and is relevant to this day.  
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7. Summary in Swedish – Svensk Sammanfattning 
 
Finns det tecken av Baumols kostnadssjuka på den finska hälsovårdssektorn? 
 
Hälsovårdskostnader har ökat drastiskt under de senaste 40 åren i de flesta industriländer. 
I Finland har totala hälsoutgifterna ökat från fyra till tio procent av BNP och utgifterna 
förväntas öka 2 % årligen under nästa årtionde. Inom 2000-talet har man gjort flera bidrag 
till hälsoekonomin om vad som orsakar kostnaderna i hälsovård. Den viktigaste 
determinanten som framställts till ökande kostnader är BNP per capita, vilket tyder på att 
ju högre inkomst desto mer hälsovård efterfrågas. Det återstående problemet är att 
inkomsttillväxten inte fullständigt förklarar fenomenet och att andra väsentliga variabler 
inte verkar påverka hälsoutgifter lika kraftigt. Varierande metoder har testats för att mäta 
arbetsproduktivitetens inverkan på hälsosektorn under senaste åren, med motstridande 
resultat. En av dessa metoder är att undersöka ifall hälsovårdssektorn drabbas av Baumols 
kostnadssjuka, vilket i teorin direkt skulle förklara hur produktivitetsskillnader ökar 
hälsoutgiftera i ett land.  
 
I denna avhandling undersöks om det finns tecken av Baumols kostnadssjuka i finska 
hälsovårdssystemet, med den metod som konstruerades av Atanda, Menclova och Reed 
(2018). Kostnadssjukan sker då två sektorer i ekonomin har en ojämn 
produktivitetstillväxt, men tillväxten i lönerna är lika. Enligt Baumols (1967) 
formalisering visar sektorn med långsam tillväxt fyra olika förändringar på marknaden: 1) 
Kostnaderna ökar relativt till resten av ekonomin, 2) efterfrågan sjunker eftersom priserna 
måste stiga i förhållande till kostnaderna i produktionen, 3) ifall efterfrågan hålls konstant 
med att en tredje part subventionerar produktionen kommer en ökande andel av 
arbetskraften förflytta sig till den sektorn där tillväxten är långsam, 4) tillväxttakten i hela 
ekonomin kommer att sjunka, eftersom subventionernas mängd växer kontinuerligt. Dessa 
fyra effekter kallas ofta för Baumols propositioner. Första propositionen anses ofta vara 
viktigast, men relativt högre kostnader till resten av ekonomin kan förekomma på flera 
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olika sätt. Därmed är det viktigt att undersöka även de andra propositionerna, så att man 
med högre sannolikhet kan identifiera en bransch som en Baumolsektor. I Atanda, 
Menclova och Reeds (2018) ekonometriskt tillämpbara modell är andelen som jobbar 
inom hälsovård en funktion av en variabel som beskriver efterfrågan av icke-
hälsoprodukter och en variabel som mäter skillnaden i produktivitet mellan hälsovård och 
resten av ekonomin. Efterfrågan av icke-hälsoprodukter förväntas ha en negativ effekt och 
produktivitetsskillnaden en positiv effekt på andelen hälsorelaterade jobb. Intuitivt kunde 
hälsovården klassas som en sektor som drabbas av kostnadssjukan, eftersom 
tjänsteproduktion har allmänt långsammare produktivitetstillväxt, kostnaderna har okat 
markant och Finland erbjuder allmän hälsovård, alltså en tredje part finansierar 
produktionen.  
  
Metoden som används i avhandlingen är en ekonometrisk regressionsanalys, där 
huvudsakliga målet är att analysera hur skillnaden i produktivitetstillväxt påverkar 
andelen av arbetskraft inom hälsovård. Produktivitetsskillnaden är i detta fall uträknad 
med att dela den totala arbetsproduktiviteten i övriga ekonomin med arbetsproduktiviteten 
i hälsovård. Ifall en ökning i produktivitetsskillnaden orsakar en ökning i 
hälsoarbetskraften, skulle detta tyda på att hälsosektorn drabbas av Baumols 
kostnadssjuka. Därutöver testas problemet även en annan regression som mäter ifall en 
ökning i totala arbetsproduktiviteten i hela regionen ökar på arbetskraften inom hälsovård. 
Datamaterialet är från finska ekonomiska regioner mellan åren 2000 och 2016. I studien 
mäts effekten med en OLS modell med fixa effekter på regionnivå. Modellen kontrolleras 
även för tidsfixa effekter samt regionsspecifika tidstrender, vilket kan minska på eventuell 
heterogenitet som kan förekomma i datamaterialet. Metoden lämpar sig för finsk data, 
eftersom det finns stora skillnader i hälsovariabler mellan regioner inom landet. I Finland 
ansvar kommunerna för primärvården och sjukhusdistrikten ansvarar för specialvård. Det 
saknas en tydlig beslutsfattningsstruktur mellan dessa nivåer och regionerna tillämpar 
tillhandahållandet av sjukvård på olika sätt.  Globalt sett rangordnas det finska 
hälsosystemet högt, men nationella skillnaderna är stora även om alla kommuner är 
verksamma inom samma fundamentala hälsosystem. 
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Enligt regressionsresultaten ökar produktivitetsskillnaden på andelen arbetskraft som 
jobbar med hälsorelaterade tjänster då efterfrågan av hälsoprodukter hålls konstant, vilket 
tyder på att två av Baumols (1967) ursprungliga propositioner är synliga. Även totala 
produktiviteten ökar på hälsoarbetskraften, vilket i teorin förutspås byggd av Atanda, 
Menclova och Reed (2018). Resultaten i studien av Finansministeriet (Ministry of 
Finance, 2013) av finska hälsovårdssystemet tyder också på att skillnaden i 
produktivitetstillväxten orsakar högre kostnader inom hälsovård. Finansministeriets 
resultat och utfallen i denna studie indikerar kraftigt att hälsosektorn i Finland påverkas 
av Baumols kostnadssjuka. Relativa kostnader för hälsovård stiger och andelen av 
arbetsuppgifterna förflyttas mot hälsobranschen, på grund av att produktiviteten har en 
kraftigare tillväxt i resterande ekonomin. Däremot är effekten inte så stor. En medelmåttlig 
årlig förändring i produktivitetsskillnadsvariabeln skulle fenomenet påverka 600-850 
individer varje år. Hela finska hälsovårdssystemet sysselsätter omkring 400 000 
människor (Statistics Finland, 2019). Det finns inte heller en tydlig trend hur 
produktiviteten i hälsosektorn och i resten av ekonomin kommer att förändras i framtiden. 
Hälsosektorn påverkas allmänt mindre av konjunktursvängningar i ekonomin, vilket 
förvränger variabelvärden en del. Allmänt kan dock Baumols kostnadssjuka inte uteslutas 
som en förklaring till både ökade kostnader för hälsovård och förändring på 
hälsoarbetskraften. 
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Appendix 
Appendix A. Variable definitions 
Table A1 Variable definitions 
Variable Measured Definition Source 
𝐿𝐻𝐿  𝐿𝐻
𝐿
 
Healthcare sector share of total labour. Statistics Finland 
(2019) 
𝜙 ³ (
𝑌𝑁𝐻
𝐿𝑁𝐻
⁄ )
(
𝑌𝐻
𝐿𝐻
⁄ )
 
Relative productivity. Measures the 
disparity in productivity between 
health sector and rest of the economy 
(sum of all other sectors in Finland). 
Statistics Finland 
(2019) 
𝑃𝑟𝑜𝑑  𝐺𝐷𝑃
𝑡𝑜𝑡𝑎𝑙 ℎ𝑜𝑢𝑟𝑠 𝑤𝑜𝑟𝑘𝑒𝑑
 
Productivity.  Statistics Finland 
(2019); Finnish 
institute for 
health and 
welfare (2020) 
𝑘  𝑌𝑁𝐻
𝑌
 
The output share of non-health sector. 
Measures the demand for non-health 
goods.  
Statistics Finland 
(2019) 
Private health 
production³ 
𝑌𝐻,𝑝𝑟𝑖𝑣𝑎𝑡𝑒
𝑌𝐻,𝑡𝑜𝑡𝑎𝑙
 
Private health output of the total health 
production. Measures the size of the 
private health sector.  
Statistics Finland 
(2019) 
Costs of 
specialised 
care/capita 
𝐶𝑆𝑝𝑒𝑐𝑖𝑎𝑙𝑖𝑠𝑒𝑑 𝑐𝑎𝑟𝑒
𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
 
Cost of the specialised care. Indicator 
of the size specialised care sector, 
within the health sector.   
Finnish institute 
for health and 
welfare (2020) 
Sickness 
allowances 
𝑅𝑒𝑐𝑖𝑝𝑖𝑒𝑛𝑡𝑠
𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
∗ 1000 
The number individuals that have 
received at least one day of sickness 
allowances.  
Finnish institute 
for health and 
welfare (2020) 
Cancer index  Index value Number of new cases of cancer. 100 = 
total average in Finland 2016. Age-
standardised. 
Finnish institute 
for health and 
welfare (2020) 
Circulatory 
disease index  
Index value Number of new diagnoses of first- and 
second-degree coronary diseases. 100 
= total average in Finland 2016. Age-
standardised. 
Finnish institute 
for health and 
welfare (2020) 
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GDP/cap growth 
rate 
𝑑. ln (
𝐺𝐷𝑃
𝑝𝑜𝑝𝑢𝑙𝑎𝑡𝑖𝑜𝑛
) 
Growth of per capita income.  Finnish institute 
for health and 
welfare (2020) 
Age > 64 𝑝𝑒𝑟𝑐𝑒𝑛𝑡
100
 
The share of the resident population 
that are more than 64 years old. 
Finnish institute 
for health and 
welfare (2020) 
Age < 15 𝑝𝑒𝑟𝑐𝑒𝑛𝑡
100
 
The share of the resident population 
that are less than 15 years old. 
Finnish institute 
for health and 
welfare (2020) 
Unemployment 𝑢𝑛𝑒𝑚𝑝𝑙𝑜𝑦𝑒𝑑
𝑙𝑎𝑏𝑜𝑢𝑟 𝑓𝑜𝑟𝑐𝑒
 
Rate of unemployment.  Finnish institute 
for health and 
welfare (2020) 
Relative public 
indebtedness 
𝑙𝑖𝑎𝑏𝑖𝑙𝑖𝑡𝑖𝑒𝑠
𝑐𝑢𝑟𝑟𝑒𝑛𝑡 𝑖𝑛𝑐𝑜𝑚𝑒
 
Percent of the public sector’s current 
income that would be required to 
offset the liabilities. Indicates the need 
of public saving.   
Finnish institute 
for health and 
welfare (2020) 
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Appendix B. Further calculations 
B1: Calculations of the fourth proposition (P4) of the cost disease 
The fourth proposition shows how the economy-wide growth will eventually slow down 
(Chapter 3.1). The calculations by Baumol (1967) for P4 is shown in the following way: 
 
We can measure the index of total output as an index of both sector’s weighted outputs as 
 
 𝐼 = 𝐵𝑁𝑃𝑆𝑌𝑁𝑃𝑆(𝑡) + 𝐵𝑃𝑆𝑌𝑃𝑆(𝑡) = 𝐵𝑁𝑃𝑆𝑎𝐿𝑁𝑃𝑆(𝑡) + 𝐵𝑃𝑆𝑏𝐿𝑃𝑆(𝑡)𝑒
𝑟𝑡  , (B1.1) 
 
where 𝐵𝑁𝑃𝑆 and 𝐵𝑃𝑆 are the sectors’ weights. By substituting equations (3.12) and (3.13) 
to (B1.1), we get 
 
𝐼 = 𝐵𝑁𝑃𝑆𝑎
𝛾𝐿(𝑡)𝑒𝑟𝑡
1 + 𝛾𝑒𝑟𝑡
+ 𝐵𝑃𝑆𝑏
𝐿(𝑡)
1 + 𝛾𝑒𝑟𝑡
𝑒𝑟𝑡   . 
(B1.2) 
 
If we assume that the total labour supply is a constant over time, we can rewrite equation 
(B1.2) as 
 
𝐼 =
𝑅𝑒𝑟𝑡
1 + 𝛾𝑒𝑟𝑡
   , 𝑅 =  𝐿(𝑡)(𝑎𝛾𝐵𝑁𝑃𝑆 + 𝑏𝐵𝑃𝑆)   . 
(B1.3) 
 
Additionally, a change in 𝐼 with respect to 𝑡 can be written as 
 
 𝜕𝐼
𝜕𝑡
=
𝑟𝑅𝑒𝑟𝑡
(1 + 𝛾𝑒𝑟𝑡)2
   
(B1.4) 
and a percentage change in 𝐼 is shown as 
 
 
𝜕𝐼
𝜕𝑡⁄
𝐼
=
𝑟𝑅𝑒𝑟𝑡
(1 + 𝛾𝑒𝑟𝑡)2
𝑅𝑒𝑟𝑡
1 + 𝛾𝑒𝑟𝑡
=
𝑟
1 + 𝛾𝑒𝑟𝑡
   . 
(B1.5) 
Finally, lim
𝑡→∞
(
𝜕𝐼
𝜕𝑡⁄
𝐼
) = 0, meaning that the growth of the index function will slow down. 
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B2: Calculation of the total productivity method effect 
 
The differences in the coefficients in Table 5.1 and Table 5.2 can theoretically be 
explained. The difference is the effects 
𝜕(
𝐿𝐻
𝐿
)
𝜕𝜙
 and 
𝜕(
𝐿𝐻
𝐿
)
𝜕𝑃𝑟𝑜𝑑
 in the theory (Atanda, Menclova 
& Reed, 2018). The application in the econometric model (eq. 4.1) in this study uses both 
variables. The calculations can be shown the following way: 
 
In equation (3.31), the derivative of  
𝐿𝐻
𝐿
 with respect to 𝑃𝑟𝑜𝑑 is shown as 
 
 𝜕 (
𝐿𝐻
𝐿 )
𝜕𝑃𝑟𝑜𝑑
=
𝜕 (
𝐿𝐻
𝐿 )
𝜕𝜙
∙
𝜕(𝜙)
𝜕𝑃𝑟𝑜𝑑
> 0  . 
(B2.1) 
To evaluate when 
𝜕(
𝐿𝐻
𝐿
)
𝜕𝜙
>
𝜕(
𝐿𝐻
𝐿
)
𝜕𝑃𝑟𝑜𝑑
, we only need to show that 
𝜕(𝜙)
𝜕𝑃𝑟𝑜𝑑
< 1. Given equation 
(3.35), we see that  
 𝜕𝜙
𝜕𝑃𝑟𝑜𝑑
=
𝑘
(1 − 𝑃𝑟𝑜𝑑 ∙ (1 − 𝑘))
2    
(B2.2) 
 
and the condition when equation (B2.2) is less than one is calculated by 
 
 
𝑘
(1 − 𝑃𝑟𝑜𝑑 ∙ (1 − 𝑘))
2 < 1 ⟺ 𝑘 < (1 − 𝑃𝑟𝑜𝑑 ∙ (1 − 𝑘))
2
 
⟺ √𝑘 < 1 − 𝑃𝑟𝑜𝑑 ∙ (1 − 𝑘) 𝑜𝑟 − √𝑘 > 1 − 𝑃𝑟𝑜𝑑 ∙ (1 − 𝑘) 
 
 
⟺ 𝑃𝑟𝑜𝑑 <
1 − √𝑘
1 − 𝑘
 𝑜𝑟 𝑃𝑟𝑜𝑑 >
1 + √𝑘
1 − 𝑘
    . 
 
(B2.3) 
These are the restricting conditions where 
𝜕(
𝐿𝐻
𝐿
)
𝜕𝜙
>
𝜕(
𝐿𝐻
𝐿
)
𝜕𝑃𝑟𝑜𝑑
 . By calculating the difference 
between these restrictions and the actual data (Statistics Finland, 2019) used in the 
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econometric estimations (Table 5.1 & Table 5.2), we can see if the theoretically expected 
coefficient should be lower as well. Therefore, suppose that the restriction variable 
𝑃𝑟𝑜𝑑𝑟𝑒𝑠 is calculated for every observation in the data set as 
𝑃𝑟𝑜𝑑𝑟𝑒𝑠|𝑖𝑡 =
1 + √𝑘𝑖𝑡
1 − 𝑘𝑖𝑡
   , 
where 𝑖 and 𝑡 are the notations for each region and year respectively (the upper limit for 
the inequality (B2.3) is used, since there are no 𝑃𝑟𝑜𝑑 values below one). Now we can test 
the difference and ratio between the actual and the restricting value to identify if the 
condition in (B2.3) is true. The tests are: 
 
𝑇𝑒𝑠𝑡1: 𝑃𝑟𝑜𝑑𝑖𝑡 − 𝑃𝑟𝑜𝑑𝑟𝑒𝑠|𝑖𝑡 > 0 
𝑇𝑒𝑠𝑡2: 𝑃𝑟𝑜𝑑𝑖𝑡
𝑃𝑟𝑜𝑑𝑟𝑒𝑠|𝑖𝑡
> 1 
 
The results of the tests: 
 
Test Obs. Mean Std.dev 99 % confidence 
interval 
% observations 
failing the test 
𝑇𝑒𝑠𝑡1 1005 8.37 0.60  [ 6.81 , 9.93 ] 25.07 % 
𝑇𝑒𝑠𝑡2 1005 1.47 0.02 [ 1.42 , 1.52 ] 25.07 % 
 
Both statistic tests are significantly true, which means that the expected change in 
𝜕(
𝐿𝐻
𝐿
)
𝜕𝜙
 is 
greater than in 
𝜕(
𝐿𝐻
𝐿
)
𝜕𝑃𝑟𝑜𝑑
   .  
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Appendix C. Alternative measurements and robustness tests 
Table A2 Hospital-district-level fixed effects estimations with relative productivity. 
Dependant variable: Healthcare sector share of the labour force (LHL). 
VARIABLES  (FE)  (2WFE)  (FErTT) 
       
ln (𝜙)  0.0862** 0.0636** 0.0684** 0.0722** 0.0914** 0.0760** 
 (0.0115) (0.0175) (0.0160) (0.0151) (0.0138) (0.0192) 
𝑘  – 1.588** – 1.090** – 1.091** – 1.183** – 1.525** – 1.379** 
 (0.0939) (0.1890) 
 
(0.247) (0.157) (0.111) (0.169) 
% private health 
production 
 – 0.023 
(0.016) 
 – 0.035* 
(0.017) 
 – 0.043* 
(0.019) 
       
ln (costs of specialised 
care/capita) 
 0.014* 
(0.007) 
 – 0.007 
(0.005) 
 0.001 
(0.005) 
       
ln (sickness allowances)  – 0.026**  – 0.013  – 0.007 
  (0.006)  (0.008)  (0.006) 
ln (cancer index)  – 0.000  – 0.004  0.003 
  (0.006)  (0.006)  (0.004) 
ln (circulatory disease 
index) 
 0.001 
(0.003) 
 0.009* 
(0.003) 
 0.002 
(0.003) 
       
GDP/cap growth rate  – 0.001  – 0.005  – 0.002 
  (0.004)  (0.005)  (0.003) 
Age > 64  0.143*  0.341**  0.064 
  (0.063)  (0.115)  (0.069) 
Age < 15  0.435*  0.727**  0.352* 
  (0.154)  (0.206)  (0.144) 
% unemployment   – 0.043*  0.014  – 0.044* 
  (0.017)  (0.034)  (0.020) 
Relative public 
indebtedness 
 – 0.007 
(0.012) 
 – 0.012 
(0.013) 
 – 0.011 
(0.010) 
       
Constant 1.552** 1.043** 1.098** 1.090** 1.053** – 0.47 
 (0.078) (0.196) (0.218) (0.169) (0.411) (1.135) 
       
Observations 357 300 357 300 357 300 
Adj. 𝑅2 0.885 0.915 0.908 0.926 0.985 0.985 
Number of regions 21 20 21 20 21 20 
Time fixed effects No No Yes Yes Yes Yes 
Indiv. region time trends No No No No Yes Yes 
F-test (time effects) - - 𝑝 =.000 𝑝 =.000 𝑝 =.438 𝑝 =.000 
F-test (time trends) - - - - 𝑝 =.421 𝑝 =.000 
Note: Cluster-robust standard errors in parentheses. F-test: tests if the specified variables are jointly 
significant in the model, H0: no significant effects. ** 𝑝 <0.01, * 𝑝 <0.05. 
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Table A3 Robustness tests of the two-way fixed effects estimations with relative 
productivity. Dependant variable: Healthcare sector share of the labour force (LHL). 
VARIABLES (FE) (2WFE) (FErTT) 
       
ln (𝜙)  0.0715** 0.0701** 0.0720** 0.0697** 0.0705** 0.0708** 
 (0.0065) (0.0058) (0.0062) (0.0054) (0.0053) (0.0047) 
𝑘  – 1.351** – 1.204** – 1.241** – 1.170** – 1.184** – 1.165** 
 (0.0901) (0.138) 
 
(0.1220) (0.118) (0.116) (0.119) 
% private health 
production 
– 0.007 
(0.008) 
 – 0.008 
(0.008) 
   
 
       
ln (costs of specialised 
care/capita) 
– 0.007 
(0.005) 
 – 0.006 
(0.005) 
   
       
ln (sickness allowances)  – 0.018* – 0.012    
  (0.008) (0.007)    
ln (cancer index)  – 0.001 – 0.000    
  (0.004) (0.004)    
ln (circulatory disease 
index) 
 0.004 
(0.004) 
0.003 
(0.003) 
 
 
  
 
       
GDP/cap growth rate    – 0.005 – 0.004 – 0.004 
    (0.003) (0.003) (0.003) 
Age > 64    0.067  0.228** 
    (0.054)  (0.055) 
Age < 15     0.116 0.297* 
     (0.090) (0.120) 
% unemployment       0.108* 
      (0.050) 
Relative public 
indebtedness 
  
 
   0.001 
(0.006) 
       
Constant 1.383** 1.257** 1.414** 1.158** 1.161** 1.055** 
 (0.084) (0.131) (0.097) (0.111) (0.106) (0.115) 
       
Observations 1 139 1 035 1 005 1 120 1 120 1 120 
Adj. 𝑅2 0.780 0.741 0.781 0.734 0.735 0.752 
Number of regions 67 69 67 70 70 70 
Time fixed effects Yes Yes Yes Yes Yes Yes 
Indiv. region time trends No No No No No No 
F-test (time effects) 𝑝 =.000 𝑝 =.000 𝑝 =.000 𝑝 =.000 𝑝 =.000 𝑝 =.000 
F-test (time trends) - - - - - - 
Note: Cluster-robust standard errors in parentheses. F-test: tests if the specified variables are jointly 
significant in the model, H0: no significant effects. ** 𝑝 <0.01, * 𝑝 <0.05. 
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Table A4 Fixed effects estimations with relative productivity, each sector’s productivity 
measured as output per hours worked. Dependant variable: Healthcare sector share of the 
labour force (LHL). 
VARIABLES  (FE)  (2WFE)  (FErTT) 
       
ln (𝜙ℎ𝑜𝑢𝑟𝑠)  0.0633** 0.0563** 0.0575** 0.0571** 0.0650** 0.0598** 
 (0.0041) (0.0051) (0.0052) (0.0051) (0.0051) (0.0053) 
𝑘  – 1.154** – 1.121** – 0.9940** – 1.135** – 1.025** – 1.177** 
 (0.0814) (0.0928) 
 
(0.1220) (0.098) (0.152) (0.110) 
% private health 
production 
 – 0.021* 
(0.008) 
 – 0.023* 
(0.009) 
 – 0.033** 
(0.008) 
       
ln (costs of specialised 
care/capita) 
 – 0.007 
(0.004) 
 – 0.004 
(0.005) 
 0.004 
(0.003) 
       
ln (sickness allowances)  – 0.002  – 0.002  0.006 
  (0.007)  (0.008)  (0.006) 
ln (cancer index)  – 0.001  – 0.001  – 0.003 
  (0.004)  (0.004)  (0.004) 
ln (circulatory disease 
index) 
 0.003 
(0.003) 
 0.002 
(0.004) 
 0.005 
(0.003) 
       
GDP/cap growth rate  – 0.001  – 0.001  – 0.000 
  (0.002)  (0.002)  (0.001) 
Age > 64  0.201**  0.301**  0.227** 
  (0.035)  (0.065)  (0.073) 
Age < 15  0.190  0.293*  0.142 
  (0.106)  (0.117)  (0.131) 
% unemployment   0.024  0.082*  0.022 
  (0.029)  (0.046)  (0.022) 
Relative public 
indebtedness 
 0.003 
(0.006) 
 0.003 
(0.006) 
 – 0.006 
(0.005) 
       
Constant 1.172** 1.121** 1.022** 1.072** 1.050** 1.073** 
 (0.075) (0.104) (0.112) (0.114) (0.140) (0.103) 
       
Observations 1 190 1 005 1 190 1 005 1 190 1 005 
Adj. 𝑅2 0.643 0.725 0.678 0.729 0.947 0.964 
Number of regions 70 67 70 67 70 67 
Time fixed effects No No Yes Yes Yes Yes 
Indiv. region time trends No No No No Yes Yes 
F-test (time effects) - - 𝑝 =.000 𝑝 =.006 𝑝 =.746 𝑝 =.000 
F-test (time trends) - - - - 𝑝 =.000 𝑝 =.000 
Note: Cluster-robust standard errors in parentheses. F-test: tests if the specified variables are jointly 
significant in the model, H0: no significant effects. ** 𝑝 <0.01, * 𝑝 <0.05. 
 
 
